Business Context and Reporting Period
Company: Bioanalytical Systems, Inc. (Note: Input metadata lists "Inotiv, Inc.", but the filing text identifies the registrant as Bioanalytical Systems, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: September 30, 2000
Business Overview: The Company is a contract research organization (CRO) providing analytical chemistry services and manufacturing scientific instruments for the pharmaceutical, medical device, and biotechnology industries. Operations are divided into two segments: Analytical Services and Products.
Key Financial Metrics (Fiscal Year 2000)
| Metric | Value (in thousands) |
|---|---|
| Total Revenue | $19,223 |
| Gross Profit | $7,004 |
| Operating Loss | $(1,192) |
| Net Loss | $(1,382) |
| Net Loss Per Share (Basic & Diluted) | $(0.30) |
| Cash and Cash Equivalents | $478 |
| Working Capital | $931 |
| Long-term Debt (less current portion) | $3,638 |
| Line of Credit Outstanding | $2,267 |
Material Changes vs. Prior Period
- Revenue: Total revenue decreased 3.2% to $19.2 million from $19.9 million in 1999. Service revenue increased 10.1% to $11.0 million, while Product revenue declined 16.6% to $8.2 million.
- Profitability: The Company reported a net loss of $1.4 million in 2000, compared to a net income of $0.6 million in 1999. Operating income turned negative ($1.2 million loss) from a positive $1.0 million in the prior year.
- Margins: Gross margin declined to 36.4% from 47.4% in 1999. Cost of service revenue increased significantly to 84.1% of service revenue (from 65.0%) due to the acquisition of T.P.S., Inc.
- Liquidity: Cash and cash equivalents dropped 75% to $0.5 million from $1.9 million, driven by capital expenditures and the acquisition of T.P.S., Inc.
- Acquisition Impact: The acquisition of T.P.S., Inc. (renamed BAS Evansville) in October 1999 added preclinical services but increased operating costs and general/administrative expenses by 17.3%.
Guidance, Outlook, and Risks
- Outlook: Management believes cash from operations and existing credit facilities will be sufficient to fund working capital and capital expenditure requirements for the foreseeable future. No firm commitments for future capital expenditures were disclosed.
- Strategic Focus: The Company is redirecting sales efforts to target pharmaceutical companies with annual revenues under $1 billion to reduce client concentration risk. It is also expanding international growth through acquisitions and distributor networks.
- Key Risks:
- Client Concentration: Over 50% of revenue is derived from the top 25 pharmaceutical companies. One major U.S. client accounted for 21% of total revenue in 2000.
- Contract Termination: Service contracts are generally terminable by clients with 30 days' notice, creating revenue volatility.
- Regulatory Compliance: Operations are subject to strict FDA GLP and GMP regulations; non-compliance could result in data disqualification or operational discontinuance.
- Legal Proceedings: A patent infringement lawsuit filed by CMA Microdialysis Holding A.B. regarding microdialysis probes is pending settlement. Management does not expect a material adverse effect.
Investor Verification Checklist
- Verify the sustainability of the 10% increase in service revenue against the 17% decline in product revenue.
- Confirm the status and financial terms of the settlement with CMA Microdialysis Holding A.B.
- Assess the impact of the $2.3 million line of credit utilization on future liquidity and covenant compliance.
- Review the client concentration risk, specifically the reliance on the single client representing 21% of revenue.
- Monitor the integration and cost structure of the newly acquired T.P.S., Inc. (BAS Evansville) facility.